Scarica l'app Stockscreener
4.78
4.82%
0.22
Pre-mercato:
4.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACHV Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.56
Aprire:
$4.57
Volume 24 ore:
1.85M
Relative Volume:
1.57
Capitalizzazione di mercato:
$490.71M
Reddito:
-
Utile/perdita netta:
$-54.65M
Rapporto P/E:
-3.6917
EPS:
-1.2948
Flusso di cassa netto:
$-49.47M
1 W Prestazione:
+4.60%
1M Prestazione:
+20.71%
6M Prestazione:
-1.24%
1 anno Prestazione:
+51.27%
Intervallo 1D:
$4.48
$4.935
Intervallo di 1 settimana:
$4.45
$4.935
Portata 52W:
$2.00
$6.15
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Nome
Achieve Life Sciences Inc
Settore
Industria
Telefono
425-686-1500
Indirizzo
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
4.78 | 468.13M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
437.22 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.74 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
820.63 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.00 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2025-11-25 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-08-21 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2024-09-27 | Iniziato | Raymond James | Strong Buy |
| 2023-05-10 | Reiterato | Maxim Group | Buy |
| 2021-06-23 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Achieve Life Sciences Inc Borsa (ACHV) Ultime notizie
Achieve Life Sciences 4Q Loss/Shr 28c >ACHV - Moomoo
[EFFECT] ACHIEVE LIFE SCIENCES, INC. SEC Filing - Stock Titan
Canaccord reiterates Achieve Life Sciences stock rating on safety data By Investing.com - Investing.com South Africa
Achieve Life Sciences (ACHV) price target decreased by 14.04% to 12.82 - MSN
Canaccord reiterates Achieve Life Sciences stock rating on safety data - Investing.com
Q3 2025 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
ACHV Should I Buy - Intellectia AI
ACHV Technical Analysis | Trend, Signals & Chart Patterns | ACHIEVE LIFE SCIENCES INC (NASDAQ:ACHV) - ChartMill
Achieve Life Sciences presents long-term cytisinicline data - Investing.com UK
Achieve Life Sciences presents long-term cytisinicline data By Investing.com - Investing.com Nigeria
Achieve Life Sciences, Inc.: cytisinicline data indicate well-tolerated safety over 52 weeks for adults quitting smoking - Traders Union
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment - The Manila Times
Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline in Smoking Cessation at ATS 2026 - Quiver Quantitative
Year-long test of quit-smoking pill cytisinicline finds low nausea - Stock Titan
Achieve Life Sciences Q1 earnings call highlights - MSN
Achieve (ACHV) Q1 2026 Earnings Transcript - AOL.com
Q2 Earnings Forecast for ACHV Issued By Zacks Research - MarketBeat
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectations - Investing.com
HC Wainwright Has Optimistic Outlook of ACHV Q2 Earnings - MarketBeat
[Form 3] ACHIEVE LIFE SCIENCES, INC. Initial Statement of Beneficial Ownership - Stock Titan
Director at ACHIEVE Life Sciences (ACHV) granted 47,250 stock options at $5.59 - Stock Titan
Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission - Seeking Alpha
Achieve Life Sciences, Inc.Common Shares (NQ: ACHV - FinancialContent
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2026 Earnings Call Transcript - Insider Monkey
Achieve Life Sciences (ACHV) registers 99.04M shares for resale by investors - Stock Titan
Achieve Life Sciences Releases Q1 2026 Financial Results - AlphaStreet
Achieve Life Sciences (ACHV) Secures $180M Financing for Cytisin - GuruFocus
Achieve Life Sciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Achieve Life Sciences Q1 2026 beats EPS expectations - Investing.com
Achieve Life Sciences Q1 2026: Loss Narrows 38.7% to -$0.19/Share - AlphaStreet
Achieve Life Sciences Q1 Earnings Call Highlights - MarketBeat
Achieve Life Sciences adds three executives to leadership team By Investing.com - Investing.com South Africa
ACHV: Achieve Aims for FDA Approval of Cytisinicline as New Smok - GuruFocus
How Should Investors Value Achieve Life Sciences (ACHV) After Q1 - GuruFocus
Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Achieve Life Sciences Closes $354M Financing, Advances Cytisinicline for Smoking & Vaping Cessation with FDA Review in 2026 - Minichart
Achieve Life Sciences Q1 loss narrows more than expected - TradingView
Q1 2026 Achieve Life Sciences Inc Earnings Call Transcript - GuruFocus
ACHV Stock Surges After Achieve Life Sciences Reports Market-Beating Q1 2026 Earnings - ChartMill
Achieve Life Sciences Adds Director Amid Board Transitions - TipRanks
Achieve Life Sciences adds three executives to leadership team - Investing.com
ACHIEVE LIFE SCIENCES ($ACHV) Releases Q1 2026 Earnings - Quiver Quantitative
Achieve Life Sciences Inc Azioni (ACHV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):